Hodnocení minimální zbytkové choroby u nemocných s De Novo akutní myeloidní leukemií léčených kombinovanou terapií Azacitidine a Venetoclax.

Investor logo
Title in English Evaluation of minimal residual disease in patients with De Novo acute myeloid leukemia treated with Azacitidine and Venetoclax combination therapy.
Authors

SEMERÁD Lukáš WEINBERGEROVÁ Barbora PODSTAVKOVÁ N. KVETKOVÁ Anežka MRKVOVÁ Zuzana VOLDŘICH Jakub PROCHÁZKOVÁ Jiřina JEŽÍŠKOVÁ Ivana FOLTA A. BORSKÝ Marek JAROŠOVÁ Marie MAYER Jiří

Year of publication 2023
Type Conference abstract
MU Faculty or unit

Faculty of Medicine

Citation
Description Evaluation of minimal residual disease in patients with De Novo acute myeloid leukemia treated with Azacitidine and Venetoclax combination therapy - conference abstract.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.

More info